Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD Nicoderm CQ ad decision being appealed to NARB by SmithKline Beecham.

This article was originally published in The Tan Sheet

Executive Summary

NAD NICODERM CQ AD DECISION APPEALED BY SMITHKLINE BEECHAM to the National Advertising Review Board, according to a NAD Case Report issued June 12. The firm disagrees with the decision of the National Advertising Division of the Council of Better Business Bureaus that its comparative advertising for Consumer Products' Nicoderm CQ nicotine replacement patches inaccurately communicates dose strengths and treatment lengths of the products being compared and should be modified. SmithKline Beecham believes NAD's solution would create confusion among consumers and asked that an NARB panel be convened to "review the truthfulness and accuracy of the advertisement at issue."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel